VXRT - Vaxart oral flu vaccine offers greater protection in human challenge study

A new study published in Cell Host and Microbe has indicated that the VXA-A1.1, an experimental oral tablet flu vaccine developed by Vaxart (NASDAQ:VXRT), offered cellular correlates of protection against the infection caused by the influenza virus. In a Phase 2 human challenge study, the subjects received either VXA-A1.1, an injected quadrivalent, inactivated influenza vaccine (IIV), or a placebo. After 60 - 90 days from the vaccination, the participants were challenged with the H1N1 influenza virus. Results from the study indicated that VXA-A1.1 led to a stronger protection against viral shedding compared to IIV. The results highlighted cellular responses were more important for the mechanism of action of VXA-A1.1 than the neutralizing antibodies. “The data show that cellular responses are potentially more relevant for protection for an oral vaccine than circulating antibody responses,” noted David McIlwain, a senior research scientist at Stanford School of Medicine, who was also the lead author of the

For further details see:

Vaxart oral flu vaccine offers greater protection in human challenge study